Published in J Exp Ther Oncol on June 25, 2003
Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) (2008) 1.67
The emerging role of large immunophilin FK506 binding protein 51 in cancer. Curr Med Chem (2011) 0.94
Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. J Pharmacol Exp Ther (2009) 0.78
A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. Am J Clin Oncol (2010) 0.76
A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy. Sci Rep (2016) 0.75
The liposomal formulation of doxorubicin. Methods Enzymol (2005) 1.62
Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res (2003) 1.39
Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol Ther (2004) 1.39
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol (2011) 1.29
Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. J Med Chem (2008) 1.28
Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta (2003) 1.11
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther (2009) 1.07
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res (2009) 1.06
Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma (2010) 1.04
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res (2010) 1.03
P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate (2004) 1.02
Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release (2002) 1.01
Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta (2002) 1.00
Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta (2006) 0.99
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther (2006) 0.99
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta (2004) 0.95
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release (2013) 0.93
Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother Pharmacol (2002) 0.93
Effects of block copolymer properties on nanocarrier protection from in vivo clearance. J Control Release (2012) 0.92
Tumor chemosensitization strategies based on apoptosis manipulations. Mol Cancer Ther (2003) 0.92
In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm (2006) 0.91
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther (2002) 0.90
Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. J Control Release (2005) 0.90
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res (2004) 0.89
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res (2004) 0.87
An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release (2004) 0.87
Disc formation in cholesterol-free liposomes during phase transition. Biochim Biophys Acta (2003) 0.87
Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv (2010) 0.86
P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther (2002) 0.86
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol Res (2007) 0.85
High ceramide content liposomes with in vivo antitumor activity. Anticancer Res (2003) 0.85
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta (2002) 0.85
In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res (2004) 0.84
Effects of phospholipid hydrolysis on the aggregate structure in DPPC/DSPE-PEG2000 liposome preparations after gel to liquid crystalline phase transition. Biochim Biophys Acta (2006) 0.84
Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm (2010) 0.82
Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol (2005) 0.82
Subcellular distribution of S100A4 and its transcriptional regulation under hypoxic conditions in gastric cancer cell line BGC823. Cancer Sci (2010) 0.82
Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Leuk Lymphoma (2010) 0.81
Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res (2004) 0.81
Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta (2003) 0.81
Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res (2004) 0.79
Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta (2002) 0.79
Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J Pharm Sci (2009) 0.79
Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes. Pharm Res (2008) 0.79
Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods Mol Biol (2010) 0.78
Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. Ther Deliv (2014) 0.77
pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice. Prostate (2005) 0.77
Immunophenotypic, cytogenetic, and clinical features of 207 cases of childhood acute lymphoblastic leukemia in china. J Pediatr Hematol Oncol (2011) 0.77
Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol (2011) 0.76
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2014) 0.76
Acute mono-megakaryoblastic leukemia associated with extreme thrombocytosis and complex karyotype abnormalities. Am J Case Rep (2013) 0.75
Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumors. Biochim Biophys Acta (2003) 0.75
[Effects of Radix Ophiopogonis decoction on embryo-fetal development in rats]. Zhongguo Zhong Yao Za Zhi (2010) 0.75
[Expression of microRNA-10a-5p in laryngeal epithelial premalignant lesions]. Zhonghua Bing Li Xue Za Zhi (2015) 0.75